A detailed look at how the US Farm Bill of 2014 & 2018, the DEA, and FDA play a role in the development of Canna-Pet and the legal status of hemp-based products in America.
Canna-Pet® is truly unique. As the pioneer of hemp-based CBD product for pets, we’ve had the unique opportunity to pioneer the hemp industry since 2013. A plant-based, benign product made with full spectrum hemp — formally registered as cannabinoid nutrition adapted for pets with the United States Patent and Trademark Office.
Since the beginning, our goal has been to use American grown hemp in our America-made products, to improve the quality of life and nutritional health of every animal on earth. To reach those goals, Canna-Pet® has operated by three basic principles:
First, our products derive from the hemp plant and are made in cGMP laboratories and are certified benign and safe for all animals;
Second, our products work and we guarantee satisfaction
Third, we follow DEA, FDA, and local guides to ensure our products are legal and available without a prescription.
“CBD works in a variety of ways and, surprisingly, it has no side effects. As a matter of fact, it is completely non-toxic.”
Dr. Raphael Mechoulam, Organic Chemist and Professor of Medicinal Chemistry, Hebrew University, Jerusalem
<<discovered THC, isolated CBD in 1963, “Father of the endocannabinoid system”>>
Our Journey to Hemp Commercialization:
Canna-Pet® created the “CBD for pets” industry with our full and broad spectrum, cannabinoid-rich, industrial hemp products in 2013. At that time we had to import all hemp from Europe, because industrial hemp could not be legally grown in the USA at all. Our innovative products remain unique, and our formulations protected.
The 2014 version of the US Farm Bill allowed Canna-Pet® to begin working with American farmers, research universities, and hemp crops. Hemp legalization allowed us to start relationships that now financially benefit thousands of Americans who contribute to, and are impacted by, the hemp business — starting with hemp farmers and product manufacturers — extending to ultimately benefit small towns, as industrial hemp proceeded from research to becoming an agricultural commodity as a commercial crop.
In September of 2014, Canna-Pet® pioneered the domestic USA hemp industry by producing the first commercial products made with American-Grown hemp in over 60 years.
After almost two years of deliberations, the US Patent and Trademark Office awarded official registration to Canna-Pet® — formal recognition that Canna-Pet® is cannabinoid nutrition adapted for pets. Canna-Pet’s formal registration is unique – there are no other cannabinoid nutritional products recognized by USPTO.
Following our groundbreaking USPTO registration in 2015, the FDA objected to language on our website, including comments made in customer testimonials regarding the healing capabilities of hemp and CBD products. Similar warning letters were issued to Diamond Walnuts, and POM Juice for health-related claims. We immediately complied with all language changes requested by the FDA, and we have had no issues subsequent to correcting the website in 2015.
“We are very excited to have partnered with Canna-Pet® and Pet Conscious to explore the potential of cannabinoid-based products to improve the health and well being of dogs suffering from anxiety, chronic lameness, cancer, and epilepsy.”
Dawn M. Boothe, DVM, MS, PhD,
Director, Clinical Pharmacology Laboratory
Canna-Pet® celebrates three years of production using exclusively US grown hemp. Hemp CBD is 1/5th of the American market for hemp products – and rapidly growing.
Canna-Pet® was featured in The New York Times “Pets on Pot” which brought national attention to the confusing status of hemp and CBD for pets. Canna-Pet® is covered in Newsweek, CNBC, Rolling Stone, Popular Science, USA Today, People Magazine, Town & Country, petMD, the Journal of the American Veterinary Medical Association, and more – as hemp awareness has grown internationally.
However, with these industry wins came new struggles. The US Department of Agriculture offered to register Canna-Pet®’s hemp product varieties as pharmaceutical controlled substances (as part of clinical research applications with universities) – which we refused and continue to refuse in today’s changing market. The DEA also caused Auburn University clinical research involving our products to be delayed, denied them approvals for their clinical work, and put our research on cancer, seizure, and pain in dogs, cats, and horses on hold for over two years.
In 2018, Canna-Pet® celebrated 5 years as the global leader in cannabinoid nutrition, with customers in over 50 countries. For many years Canna-Pet® has worked to educate veterinarians, lawmakers, and the public in the USA about industrial hemp and cannabinoid science. Our efforts were rewarded with the formal protection of industrial hemp as an American agricultural/food crop with the 2018 Farm Bill’s passage into law. In December of 2018, the Farm Bill was formally signed into law and hemp prohibition officially ends!
One day after the 2018 Farm Bill was signed the FDA issued further guidance on hemp – their “pathway for commercialization” officially declared several forms of hemp – including hulled hemp seed, hemp seed protein, and other forms used in Canna-Pet® products – as GRAS (Generally Recognized As Safe) and therefore universally permitted in food and supplements.
Canna-Pet® attained significant progress in the advancement of hemp-CBD clinical research in animals, when the DEA acquiesced and allowed Canna-Pet® CBD-rich products to proceed in Auburn’s research trials as proprietary, broad-spectrum hemp, without designation as a pharmaceutical or controlled substance.
However, the end of the prohibition on hemp has not necessarily ended the purported prohibition on discussion of “CBD” in the context of nutrition, as the FDA still hopes to make CBD a pharmaceutical/drug when extracted from marijuana and purified as an isolate — such as in Epidolex®. The FDA still specifically precluded discussion or mention of therapeutic applications of CBD in products while pharmaceutical applications (drugs) with the compound are still under review/consideration.
Thankfully, the FDA for some time has clearly carved out pharmaceutical isolates — compounds like “CBD” or “CBD and THC”— separately from broad spectrum industrial hemp products like Canna-Pet®. In June of 2018, the World Health Organization (WHO)